Erowid.org: Erowid Reference 1009 : Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentrations and on the increase in stritatal neurotensin and dynorphin A concentrations : Tirzite D, Tirzitis G, Vigante B, Duburs G

Erowid References Database

Tirzite D, Tirzitis G, Vigante B, Duburs G. “Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentrations and on the increase in stritatal neurotensin and dynorphin A concentrations”. Biochem Pharmacol. 1993;46(4):770-772. <a name="ref">Tirzite D, Tirzitis G, Vigante B, Duburs G.</a> <a href="/references/1009">"Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentrations and on the increase in stritatal neurotensin and dynorphin A concentrations"</a> <i>Biochem Pharmacol</i>. 1993;46(4):770-772.
Text Abstract (this page) Full Text - English (private) Show Articles by Tirzite D Tirzitis G Vigante B Duburs G Article IDs Erowid RefID: 1009 PubMedID: unknown Collections Hofmann Collection MDMA Collection All References	Abstract The concentration of serotonin (5-HT) measured in rat striatum was reduced to 75% of control 1 week after a single subcutaneous administration of d/-3,4-methylenedioxymethamphetamine (MDMA, 20 mg/kg). This decrease was prevented by pretreating the animals with ritanserin. Eighteen hours after MDMA (20 mg/kg), striatal concentrations of neurotensin-like immunoreactivity (NTLI) and of dynorphin A-like immunoreactivity (DLI) were increased to 250 and 487% of control, respectively, but ritanserin failed to prevent these changes. This study supports a role for 5-HT2 receptors in the mechanism by which a single high dose of MDMA induces neuronal damage to the serotonergic system, but not the MDMA-induced increase in central NTLI and DLI concentrations.
Comments and Responses to this Article #
Submit Comment

[ Cite HTML ]